On the other hand, a recent clinical trial reported that mogamulizumab (anti-CCR4) improved the OMDS in HAM/TSP patients (21), with the most pronounced improvements in participants who had enrolled at an early stage of the disease (disease duration, <10 y; OMDS <5). This evidence concerns the gene CCR4 and tropical spastic paraparesis.